Potent malaria transmission-blocking antibody responses elicited by Plasmodium falciparum Pfs25 expressed in Escherichia coli after successful protein refolding

Infection and Immunity

Volumn 82, Issue 4, 2014, Pages 1453-1459

  Kumar, Rajesh ^a   Angov, Evelina ^b   Kumar, Nirbhay ^a  

^a TULANE UNIVERSITY   (United States)

^b Walter Reed Army Institute for Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOCKING ANTIBODY; EPITOPE; FREUND ADJUVANT; MALARIA VACCINE; MONTANIDE ISA 51; PLASMODIUM FALCIPARUM PFS25 PROTEIN; PROTOZOAL PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FEMALE; IMMUNIZATION; IMMUNOFLUORESCENCE TEST; IMMUNOGENICITY; MALARIA; MOUSE; NONHUMAN; PLASMODIUM FALCIPARUM; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEIN REFOLDING; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; ESCHERICHIA COLI; FEMALE; IMMUNOGLOBULIN G; MALARIA VACCINES; MALARIA, FALCIPARUM; MICE; MICE, INBRED BALB C; PLASMODIUM FALCIPARUM; PROTEIN FOLDING; PROTOZOAN PROTEINS;

EID: 84896462279     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01438-13     Document Type: Article

References (43)

1. WHO. 2011. World malaria report 2011. WHO, Geneva, Switzerland.
2. Murray CJ, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, Haring D, Fullman N, Naghavi M, Lozano R, Lopez AD. 2012. Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 379:413-431. http://dx.doi.org/10.1016/S0140-6736(12)60034-8.
3. Miotto O, Almagro-Garcia J, Manske M, Macinnis B, Campino S, Rockett KA, Amaratunga C, Lim P, Suon S, Sreng S, Anderson JM, Duong S, Nguon C, Chuor CM, Saunders D, Se Y, Lon C, Fukuda MM, Amenga-Etego L, Hodgson AV, Asoala V, Imwong M, Takala-Harrison S, Nosten F, Su XZ, Ringwald P, Ariey F, Dolecek C, Hien TT, Boni MF, Thai CQ, Amambua-Ngwa A, Conway DJ, Djimdé AA, Doumbo OK, Zongo I, Ouedraogo JB, Alcock D, Drury E, Auburn S, Koch O, Sanders M, Hubbart C, Maslen G, Ruano-Rubio V, Jyothi D, Miles A, O'Brien J, Gamble C, Oyola SO, Rayner JC, Newbold CI, Berriman M, Spencer CC, McVean G, Day NP, White NJ, Bethell D, Dondorp AM, Plowe CV, Fairhurst RM, Kwiatkowski DP. 2013. Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nat. Genet. 45:648-655. http://dx.doi.org/10.1038/ng.2624.
4. Kaslow DC. 2002. Transmission-blocking vaccines. Chem. Immunol. 80: 287-307. http://dx.doi.org/10.1159/000058850.
5. Kumar N. 2007. A vaccine to prevent transmission of human malaria: a long way to travel on a dusty and often bumpy road. Curr. Sci. 92:1535-1544.
6. Smith TA, Chitnis N, Briët OJ, Tanner M. 2011. Uses of mosquito-stage transmission-blocking vaccines against Plasmodium falciparum. Trends Parasitol. 27:190-196. http://dx.doi.org/10.1016/j.pt.2010.12.011.
7. Ponnudurai T, van Gemert GJ, Bensink T, Lensen AH, Meuwissen JH. 1987. Transmission blockade of Plasmodium falciparum: its variability with gametocyte numbers and concentration of antibody. Trans. R. Soc. Trop. Med. Hyg. 81:491-493. http://dx.doi.org/10.1016/0035-9203(87)90172-6.
8. Outchkourov NS, Roeffen W, Kaan A, Jansen J, Luty A, Schuiffel D, van Gemert GJ, van de Vegte-Bolmer M, Sauerwein RW, Stunnenberg HG. 2008. Correctly folded Pfs48/45 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in mice. Proc. Natl. Acad. Sci. U. S. A. 105:4301-4305. http://dx.doi.org/10.1073/pnas.0800459105.
9. Chowdhury DR, Angov E, Kariuki T, Kumar N. 2009. A potent malaria transmission blocking vaccine based on codon harmonized full length Pfs48/45 expressed in Escherichia coli. PLoS One 4:e6352. http://dx.doi.org/10.1371/journal.pone.0006352.
10. Tachibana M, Wu Y, Iriko H, Muratova O, MacDonald NJ, Sattabongkot J, Takeo S, Otsuki H, Torii M, Tsuboi T. 2011. N-terminal prodomain of Pfs230 synthesized using a cell-free system is sufficient to induce complement-dependent malaria transmission-blocking activity. Clin. Vaccine Immunol. 18:1343-1350. http://dx.doi.org/10.1128/CVI.05104-11.
11. Kaslow DC, Quakyi IA, Syin C, Raum MG, Keister DB, Coligan JE, McCutchan TF, Miller LH. 1988. A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains. Nature 333:74-76. http://dx.doi.org/10.1038/333074a0.
12. Barr PJ, Green KM, Gibson HL, Bathurst IC, Quakyi IA, Kaslow DC. 1991. Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals. J. Exp. Med. 174:1203-1208. http://dx.doi.org/10.1084/jem.174.5.1203.
13. Gozar MM, Price VL, Kaslow DC. 1998. Saccharomyces cerevisiae-secreted fusion proteins Pfs25 and Pfs28 elicit potent Plasmodium falciparum transmission-blocking antibodies in mice. Infect. Immun. 66:59-64.
14. Kaslow DC, Shiloach J. 1994. Production, purification and immunogenicity of a malaria transmission-blocking vaccine candidate: TBV25H expressed in yeast and purified using nickel-NTA agarose. Biotechnology 12:494-499. http://dx.doi.org/10.1038/nbt0594-494.
15. Tsuboi T, Takeo S, Iriko H, Jin L, Tsuchimochi M, Matsuda S, Han ET, Otsuki H, Kaneko O, Sattabongkot J, Udomsangpetch R, Sawasaki T, Torii M, Endo Y. 2008. Wheat germ cell-free system-based production of malaria proteins for discovery of novel vaccine candidates. Infect. Immun. 76:1702-1708. http://dx.doi.org/10.1128/IAI.01539-07.
16. Farrance CE, Chichester JA, Musiychuk K, Shamloul M, Rhee A, Manceva SD, Jones RM, Mamedov T, Sharma S, Mett V, Streatfield SJ, Roeffen W, van de Vegte-Bolmer M, Sauerwein RW, Wu Y, Muratova O, Miller L, Duffy P, Sinden R, Yusibov V. 2011. Antibodies to plantproduced Plasmodium falciparum sexual stage protein Pfs25 exhibit transmission blocking activity. Hum. Vaccine 7:191-198. http://dx.doi.org/10.4161/hv.7.0.14588.
17. Gregory JA, Li F, Tomosada LM, Cox CJ, Topol AB, Vinetz JM, Mayfield S. 2012. Algae-produced Pfs25 elicits antibodies that inhibit malaria transmission. PLoS One 7:e37179. http://dx.doi.org/10.1371/journal.pone.0037179.
18. Lobo CA, Dhar R, Kumar N. 1999. Immunization of mice with DNAbased Pfs25 elicits potent malaria transmission-blocking antibodies. Infect. Immun. 67:1688-1693.
19. Coban C, Philipp MT, Purcell JE, Keister DB, Okulate M, Martin DS, Kumar N. 2004. Induction of Plasmodium falciparum transmissionblocking antibodies in nonhuman primates by a combination of DNA and protein immunizations. Infect. Immun. 72:253-259. http://dx.doi.org/10.1128/IAI.72.1.253-259.2004.
20. LeBlanc R, Vasquez Y, Hannaman D, Kumar N. 2008. Markedly enhanced immunogenicity of a Pfs25 DNA-based malaria transmissionblocking vaccine by in vivo electroporation. Vaccine 26:185-192. http://dx.doi.org/10.1016/j.vaccine.2007.10.066.
21. Kumar R, Nyakundi R, Kariuki T, Ozwara H, Nyamongo O, Mlambo G, Ellefsen B, Hannaman D, Kumar N. 2013. Functional evaluation of malaria Pfs25 DNA vaccine by in vivo electroporation in olive baboons. Vaccine 31:3140-3147. http://dx.doi.org/10.1016/j.vaccine.2013.05.006.
22. Saxena AK, Singh K, Su HP, Klein MM, Stowers AW, Saul AJ, Long CA, Garboczi DN. 2006. The essential mosquito-stage P25 and P28 proteins from Plasmodium form tile-like triangular prisms. Nat. Struct. Mol. Biol. 13:90-91. http://dx.doi.org/10.1038/nsmb1024.
23. Wu Y, Ellis RD, Shaffer D, Fontes E, Malkin EM, Mahanty S, Fay MP, Narum D, Rausch K, Miles AP, Aebig J, Orcutt A, Muratova O, Song G, Lambert L, Zhu D, Miura K, Long C, Saul A, Miller LH, Durbin AP. 2008. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS One 3:e2636. http://dx.doi.org/10.1371/journal.pone.0002636.
24. Tsai CW, Duggan PF, Shimp RL, Jr, Miller LH, Narum DL. 2006. Overproduction of Pichia pastoris or Plasmodium falciparum protein disulfide isomerase affects expression, folding and O-linked glycosylation of a malaria vaccine candidate expressed in P. pastoris. J. Biotechnol. 121: 458-470. http://dx.doi.org/10.1016/j.jbiotec.2005.08.025.
25. Kubler-Kielb J, Majadly F, Wu Y, Narum DL, Guo C, Miller LH, Shiloach J, Robbins JB, Schneerson R. 2007. Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25. Proc. Natl. Acad. Sci. U. S. A. 104: 293-298. http://dx.doi.org/10.1073/pnas.0609885104.
26. Arakawa T, Komesu A, Otsuki H, Sattabongkot J, Udomsangpetch R, Matsumoto Y, Tsuji N, Wu Y, Torii M, Tsuboi T. 2005. Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum. Infect. Immun. 73:7375-7380. http://dx.doi.org/10.1128/IAI.73.11.7375-7380.2005.
27. Wu Y, Przysiecki C, Flanagan E, Bello-Irizarry SN, Ionescu R, Muratova O, Dobrescu G, Lambert L, Keister D, Rippeon Y, Long CA, Shi L, Caulfield M, Shaw A, Saul A, Shiver J, Miller LH. 2006. Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex. Proc. Natl. Acad. Sci. U. S. A. 103:18243-18248. http://dx.doi.org/10.1073/pnas.0608545103.
28. Matsumoto M, Misawa S, Tsumoto K, Kumagai I, Hayashi H, Kobayashi Y. 2003. On-column refolding and characterization of soluble human interleukin-15 receptor alpha-chain produced in Escherichia coli. Protein Expr. Purif. 31:64-71. http://dx.doi.org/10.1016/S1046-5928(03)00143-8.
29. Singh SM, Upadhayay AK, Panda AK. 2008. Solubilization at high pH results in improved recovery of proteins from inclusion bodies of E. coli. J. Chem. Technol. Biotechnol. 83:1126-1134. http://dx.doi.org/10.1002/jctb.1945.
30. Kaslow DC, Bathurst IC, Lensen T, Ponnudurai T, Barr PJ, Keister DB. 1994. Saccharomyces cerevisiae recombinant Pfs25 adsorbed to alum elicits antibodies that block transmission of Plasmodium falciparum. Infect. Immun. 62:5576-5580.
31. Angov E, Hillier CJ, Kincaid RL, Lyon JA. 2008. Heterologous protein expression is enhanced by harmonizing the codon usage frequencies of the target gene with those of the expression host. PLoS One 3:e2189. http://dx.doi.org/10.1371/journal.pone.0002189.
32. Ifediba T, Vanderberg JP. 1981. Complete in vitro maturation of Plasmodium falciparum gametocytes. Nature 294:364-366. http://dx.doi.org/10.1038/294364a0.
33. Vermeulen AN, Ponnudurai T, Lensen AH, Roeffen WF, Meuwissen JE. 1983. The purification of Plasmodium falciparum macrogametes and/or zygotes prepared from in vitro cultures. Trans. R. Soc. Trop. Med. Hyg. 77:753-755. http://dx.doi.org/10.1016/0035-9203(83)90280-8.
34. Quakyi IA, Carter R, Rener J, Kumar N, Good MF, Miller LH. 1987. The 230-kDa gamete surface protein of Plasmodium falciparum is also a target for transmission-blocking antibodies. J. Immunol. 139:4213-4217.
35. Carter R, Graves PM, Keister DB, Quakyi IA. 1990. Properties of epitopes of Pfs 48/45, a target of transmission blocking monoclonal antibodies, on gametes of different isolates of Plasmodium falciparum. Parasite Immunol. 12:587-603. http://dx.doi.org/10.1111/j.1365-3024.1990.tb00990.x.
36. Gregory JA, Topol AB, Doerner DZ, Mayfield S. 2013. Alga-produced cholera toxin-pfs25 fusion proteins as oral vaccines. Appl. Environ. Microbiol. 79:3917-3925. http://dx.doi.org/10.1128/AEM.00714-13.
37. Patra AK, Mukhopadhyay R, Mukhija R, Krishnan A, Garg LC, Panda AK. 2000. Optimization of inclusion body solubilization and renaturation of recombinant human growth hormone from Escherichia coli. Protein Expr. Purif. 18:182-192. http://dx.doi.org/10.1006/prep.1999.1179.
38. Fries HC, Lamers MB, Smits MA, Ponnudurai T, Meuwissen JH. 1989. Characterization of epitopes on the 25 kD protein of the macrogametes/zygotes of Plasmodium falciparum. Parasite Immunol. 11:31-45. http://dx.doi.org/10.1111/j.1365-3024.1989.tb00646.x.
39. Lyles MM, Gilbert HF. 1991. Catalysis of the oxidative folding of ribonuclease A by protein disulfide isomerase: dependence of the rate on the composition of the redox buffer. Biochemistry 30:613-619. http://dx.doi.org/10.1021/bi00217a004.
40. Chakravarthi S, Jessop CE, Bulleid NJ. 2006. The role of glutathione in disulphide bond formation and endoplasmic-reticulum-generated oxidative stress. EMBORep. 7:271-275. http://dx.doi.org/10.1038/sj.embor.7400645.
41. Chakravarthi S, Bulleid NJ. 2004. Glutathione is required to regulate the formation of native disulfide bonds within proteins entering the secretory pathway. J. Biol. Chem. 279:39872-39879. http://dx.doi.org/10.1074/jbc.M406912200.
42. Monahan FJ, German JB, Kinsella JE. 1995. Effect of pH and temperature on protein unfolding and thiol/disulfide interchange reactions during heat-induced gelation of whey protein. J. Agric. Food Chem. 43:46-52. http://dx.doi.org/10.1021/jf00049a010.
43. Mishra R, Seckler R, Bhat R. 2005. Efficient refolding of aggregationprone citrate synthase by polyol osmolytes: how well are protein folding and stability aspects coupled? J. Biol. Chem. 280:15553-15560. http://dx.doi.org/10.1074/jbc.M410947200.